Panaxadiol Attenuates Brain Damage by Inhibiting Ferroptosis in a Rat Model of Cerebral Hemorrhage
Drug Development Research · 2025
DOI: 10.1002/ddr.70079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Min Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center of Encephalopathy, Changchun University of Traditional Chinese Medicine Affiliated Third Clinical Hospital, Changchun, Jilin, China. Hauptthemen laut MEDLINE: Cerebral Hemorrhage, Ferroptosis, Ginsenosides, Neuroprotective Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben.
Abstract (Originalsprache)
Intracerebral hemorrhage (ICH) is the most common subtype of hemorrhage stroke, with a high disability, morbidity and mortality rate globally. Panaxadiol (PD), a triterpenoid sapogenin monomer, is isolated from the roots of ginseng, which has shown a variety of biological properties, such as anti‐inflammation, anti‐cancer, and neuroprotection. However, its effect and mechanism on ICH were still unknown. Thirty‐six rats were randomly divided into six group ( n = 6), namely, sham, ICH, ICH + 5 mg/kg PD, ICH + 10 mg/kg PD, ICH + 20 mg/kg PD, and ICH + 10 mg/kg PD + 50 mg/kg vismodegib. Rats were treated with type IV collagenase to induce an in vivo model of ICH, and then intraperitoneally injected with PD (5, 10 and 20 mg/kg) and 50 mg/kg vismodegib (an inhibitor of hedgehog signal). The effect and potential mechanism of PD on ICH were explored by behavioral test, brain water content measurement, Evans blue detection, hematoxylin‐eosin (HE) staining, iron level examination, Prussian blue staining, western blot and immunohistochemistry, respectively. An increase in the mNSS (13.17 ± 1.17), and a decrease in the rotarod latency (40.67 ± 9.31), modified Garcia score (9.83 ± 1.47), forelimb use times (3.33 ± 0.82), left forepaw placements (29.90 ± 4.38) and left turns (17.34 ± 3.55) in ICH rats were reversed with the PD treatment (6.83 ± 0.75, 113.5 ± 11.95, 17.50 ± 1.87, 8.17 ± 0.98, 63.56 ± 9.84, and 42.13 ± 4.52 respectively). PD treatment reduced the brain water content (73.13 ± 3.16 vs. 86.82 ± 4.74), the level of Evans blue (2.14 ± 0.25 vs. 4.03 ± 0.20) and cerebral hemorrhage in ICH rats. Also, PD injection decreased the iron level (0.06 ± 0.005 vs. 0.17 ± 0.02) and the expression of ACSL4 (0.56 ± 0.07 vs. 1.23 ± 0.16), with the increased expression of GPX4 (1.14 ± 0.08 vs. 0.21 ± 0.03) in ICH rats. Mechanically, PD treatment restored the decreased expression of SHH (0.96 ± 0.13 vs. 0.20 ± 0.03), GLI1 (0.89 ± 0.13 vs. 0.06 ± 0.007) and PTCH (0.75 ± 0.05 vs. 0.10 ± 0.01) in ICH rats. Inhibition of SHH signaling by vismodegib reversed the ameliorative effect of PD on ICH rats. PD improved brain damage by suppressing ferroptosis via the activation of the SHH/GLI signaling pathway, which could lay a theoretical foundation for the treatment of ICH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Encephalopathy, Changchun University of Traditional Chinese Medicine Affiliated Third Clinical Hospital, Changchun, Jilin, China.
- Center of Encephalopathy, The Third Clinical Hospital affiliated to Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China.
ORCID-Profile: Yu Wang
Zitieren
APA
Zhao, M., Wang, Y., Li, J., Wen, Q., Liu, Y., & Zhao, Y. (2025). Panaxadiol Attenuates Brain Damage by Inhibiting Ferroptosis in a Rat Model of Cerebral Hemorrhage. Drug Development Research. https://doi.org/10.1002/ddr.70079
Vancouver
Zhao M, Wang Y, Li J, Wen Q, Liu Y, Zhao Y. Panaxadiol Attenuates Brain Damage by Inhibiting Ferroptosis in a Rat Model of Cerebral Hemorrhage. Drug Development Research. 2025. doi:10.1002/ddr.70079
BibTeX
@article{Zhao2025,
author = {Zhao, Min and Wang, Yu and Li, Jing and Wen, Quan and Liu, Yue and Zhao, Yanan},
title = {Panaxadiol Attenuates Brain Damage by Inhibiting Ferroptosis in a Rat Model of Cerebral Hemorrhage},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70079}
}
EUVIMED